COST-UTILITY ANALYSIS OF SOFOSBUVIR FOR TREATMENT OF GENOTYPE2 CHRONIC HEPATITIS C IN JAPAN

被引：1
|
作者：
Igarashi, A. [1 ]
Tang, W. [1 ]
Cure, S. [2 ]
Guerra, I [2 ]
Lopresti, M. [3 ]
Tsutani, K. [1 ]
机构：
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo, Japan
[2] OptumInsight, Uxbridge, Middx, England
[3] Junicon Japan Inc, Minato Ku, Tokyo, Japan
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.827
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI30
引用
收藏
页码：A368 / A368
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2
    Sugimoto, Kayo
    Kim, Soo Ki
    Kim, Soo Ryang
    Kobayashi, Mana
    Kato, Airi
    Morimoto, Eri
    Imoto, Susumu
    Kim, Chi Wan
    Tanaka, Yasuhito
    Kudo, Masatoshi
    Yano, Yoshihiko
    Hayashi, Yoshitake
    DIGESTIVE DISEASES, 2016, 34 (06) : 627 - 631
  • [22] Cost-effectiveness of sofosbuvir/ribavirin in patients with genotype 2 chronic hepatitis C: An analysis with real-world outcomes from a multicenter cohort in Japan
    Furusyo, Norihiro
    Igarashi, Ataru
    Ogawa, Eiichi
    Nomura, Hideyuki
    Dohmen, Kazufumi
    Higashi, Nobuhiko
    Takahashi, Kazuhiro
    Kawano, Akira
    Azuma, Koichi
    Satoh, Takeaki
    Nakamuta, Makoto
    Koyanagi, Toshimasa
    Kato, Masaki
    Shimoda, Shinji
    Kajiwara, Eiji
    Hayashi, Jun
    HEPATOLOGY, 2017, 66 : 856A - 857A
  • [23] COST-EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR FOR THE TREATMENT OF GENOTYPE 1 OR 4 CHRONIC HEPATITIS C IN ENGLAND AND WALES
    Howells, R.
    Trehame, C.
    VALUE IN HEALTH, 2015, 18 (07) : A589 - A589
  • [24] Treatment of Chronic Hepatitis C Genotype 3 With Ledipasvir and Sofosbuvir: An Observational Study
    Dar, Gulzar A.
    Yattoo, Ghulam N.
    Gulzar, Ghulam M.
    Sodhi, Jaswinder S.
    Gorka, Suresh
    Laway, Mushtaq A.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2021, 11 (02) : 227 - 231
  • [25] Sofosbuvir for treatment of chronic hepatitis C
    Sarah Kattakuzhy
    Rachel Levy
    Shyam Kottilil
    Hepatology International, 2015, 9 : 161 - 173
  • [26] Sofosbuvir for treatment of chronic hepatitis C
    Kattakuzhy, Sarah
    Levy, Rachel
    Kottilil, Shyam
    HEPATOLOGY INTERNATIONAL, 2015, 9 (02) : 161 - 173
  • [27] Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan
    Mizokami, Masashi
    Liu, Lauren J.
    Fujiyama, Naoto
    Littman, Marcus
    Yuan, Jason
    Sekiya, Tomoko
    Hedskog, Charlotte
    Ng, Leslie J.
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (01) : 129 - 141
  • [28] COST-UTILITY ANALYSIS OF TENOFOVIR IN COMPARISON WITH OTHER NUCLEOSIDE ANALOGUES (AN) IN CHRONIC HEPATITIS B (CHB) TREATMENT
    Gwiosda, B.
    Krzystek, J.
    Niesyczynski, G.
    Osiewalski, K.
    Mierzejewski, P.
    Kazmierski, M.
    Wladysiuk, M.
    Plisko, R.
    VALUE IN HEALTH, 2011, 14 (07) : A280 - A280
  • [29] Cost-effectiveness of Sofosbuvir plus Ledipasvir Antiviral Treatment for Elderly Patients with Chronic Hepatitis C Genotype 1
    Ciaccio, Antonio
    Cortesi, Paolo
    Bellelli, Giuseppe
    Rota, Matteo
    Rota, Monica
    Mantovani, Lorenzo G.
    Annoni, Giorgio
    Strazzabosco, Mario
    HEPATOLOGY, 2015, 62 : 919A - 919A
  • [30] Sofosbuvir and Ledipasvir/Sofosbuvir for the Treatment of Patients with Chronic Genotype 6 Hepatitis C Virus Infection: Integrated Analysis of Phase 2 and Phase 3 Studies
    Gane, Edward J.
    Chuang, Wan-Long
    Hassanein, Tarek I.
    Kowdley, Kris V.
    Lawitz, Eric
    Gao, Bing
    Mo, Hongmei
    Hyland, Robert H.
    Yang, Jenny C.
    De-Oertel, Shampa
    Brainard, Diana M.
    Knox, Steven J.
    McHutchison, John G.
    Lai, Ching-Lung
    Chan, Henry Lik-Yuen
    HEPATOLOGY, 2015, 62 : 761A - 761A
12345